US2001012629A1PendingUtilityA1

Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids

50
Priority: Mar 11, 1996Filed: Mar 2, 2001Published: Aug 9, 2001
Est. expiryMar 11, 2016(expired)· nominal 20-yr term from priority
Inventors:Renata Maria Anna Cavaliere VeselyClaudio De Simone
A61P 1/16A61P 1/00A61K 31/7016A61K 31/575A61K 35/747A61K 35/74C12N 1/20C12R 2001/225C12R 2001/46A61K 35/744C12N 1/205
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Strains of bacteria characterized by exhibiting: (a) a 7α-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b); and a pharmaceutical composition using one or more of such strains and use of same for preventing and treating diseases associated with or caused by an altered metabolism of bile acids.

Claims

exact text as granted — not AI-modified
What is claimed as new and desired to be secured by Letters Patent of the United States is:  
     
         1 . A bacteria strain characterized by exhibiting: (a) a 7α-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b).  
     
     
         2 . The strain of    claim 1   , which is a gram-positive bacteria strain.  
     
     
         3 . The strain of    claim 1   , belonging to a species selected from  Streptococcus thermophilus, Streptococcus faecium,  and  Lactobacillus bulgaricus.    
     
     
         4 . The strain of    claim 3   , wherein the bacteria strain is  Streptococcus thermophilus  YS 52 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1670.  
     
     
         5 . The strain of    claim 3   , wherein the bacteria strain is  Streptococcus thermophilus  YS 46, deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1668.  
     
     
         6 . The strain of    claim 3   , wherein the bacteria strain is  Streptococcus thermophilus  YS 48, deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1669.  
     
     
         7 . The strain of    claim 3   , wherein the bacteria strain is  Streptococcus faecium  SF 3, deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1671.  
     
     
         8 . The strain of    claim 3   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 1 deposited with the CNCM, Collection Nationale de Cultures de microorganismes, Institut Pasteur, under the accession number I-1664.  
     
     
         9 . The strain of    claim 3   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1665.  
     
     
         10 . The strain of    claim 3   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 7 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1666.  
     
     
         11 . The strain of    claim 3   , wherein the bacteria strain is Lactobacillus bulgaricus LB 77 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1667.  
     
     
         12 . A pharmaceutical composition for preventing and/or treating diseases associated with or caused by an altered metabolism of bile acids, comprising an effective amount capable of producing a normalizing effect on such an altered metabolism in a patient suffering therefrom, of 
 (1) at least one bacteria strain provided with: (a) a 7α-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b), and    (2) a pharmaceutically acceptable carrier.    
     
     
         13 . The pharmaceutical composition of    claim 12   , wherein said at least one bacteria strain is a gram-positive bacteria strain.  
     
     
         14 . The composition of    claim 12   , wherein said at least one bacteria strain belongs to a species selected from the group consisting of  Streptococcus thermophilus, Streptococcus faecium , and  Lactobacillus bulgaricus.    
     
     
         15 . The composition of    claim 14   , wherein the bacteria strain is  Streptococcus thermophilus  YS 52 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1670.  
     
     
         16 . The composition of    claim 14   , wherein the bacteria strain is  Streptococcus thermophilus  YS 46 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1668.  
     
     
         17 . The composition of    claim 14   , wherein the bacteria strain is  Streptococcus thermophilus  YS 48 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1669.  
     
     
         18 . The composition of    claim 14   , wherein the bacteria strain is  Streptococcus faecium  SF 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1671.  
     
     
         19 . The composition of    claim 14   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 1 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1664.  
     
     
         20 . The composition of    claim 14   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1665.  
     
     
         21 . The composition of    claim 14   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 7 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1666.  
     
     
         22 . The composition of    claim 14   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 77 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1667.  
     
     
         23 . The composition of    claim 12   , comprising 10 3  to 10 13  cells of the bacteria strain per gram of composition.  
     
     
         24 . The composition of    claim 12   , further comprising lactulose.  
     
     
         25 . The composition of    claim 12   , further comprising bile acid-based preparations, such as ursodeoxycholic acid and tauroursodeoxycholic acid.  
     
     
         26 . A method for preventing and treating diseases caused by or associated with an altered metabolism of bile acids, said method comprising administering at least one bacteria strain characterized by exhibiting: 
 (a) a 7α-dehydroxylase activity of less than 50%, and    (b) a bile acid deconjugation activity of less than 50%, and descendants, or a mutant or derivative thereof preserving activities (a) and (b).    
     
     
         27 . A method of    claim 26   , wherein the at least one bacteria strain is a gram-positive bacteria strain.  
     
     
         28 . The method of    claim 26   , wherein the bacteria strain belongs to a species selected from the group consisting of  Streptococcus thermophilus, Streptococcus faecium,  and  Lactobacillus bulgaricus.    
     
     
         29 . The method of    claim 28   , wherein the bacteria strain is  Streptococcus thermophilus  YS 52 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1670.  
     
     
         30 . The method of    claim 28   , wherein the bacteria strain is  Streptococcus thermophilus  YS 46 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1668.  
     
     
         31 . The method of    claim 28   , wherein the bacteria strain is  Streptococcus thermophilus  YS 48 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1669.  
     
     
         32 . The method of    claim 28   , wherein the bacteria strain is  Streptococcus faecium  SF 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1671.  
     
     
         33 . The method of    claim 28   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 1 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1664.  
     
     
         34 . The method of    claim 28   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 3 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1665.  
     
     
         35 . The method of    claim 28   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 7 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1666.  
     
     
         36 . The method of    claim 28   , wherein the bacteria strain is  Lactobacillus bulgaricus  LB 77 deposited with the CNCM, Collection Nationale de Cultures de Microorganismes, Institut Pasteur, under the accession number I-1667.

Join the waitlist — get patent alerts

Track US2001012629A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.